PD-1 (CD279) is a type I transmembrane protein composed of 288 amino acid residues, belonging to the CD28 family. It is widely expressed on a variety of immune cells, such as activated T cells, B cells, NK cells and DC cells. PD-L1 (CD274) is a ligand of PD-1, that is, a protein that can pair and bind to PD-1. It consists of 290 amino acid residues, mainly including short cytoplasmic tail region, transmembrane region, and IgV and IGC-like extracellular domains. PD-L1 is expressed in tumor cells and antigen presenting cells (APC). PD-1 and its ligand PD-L1 pathway control the induction and maintenance of immune tolerance in the tumor microenvironment. PD-1/PD-L1 activity is responsible for the activation, proliferation and cytotoxic secretion of T cells in cancer, thereby reducing the degenerate anti-tumor immune response.

Filter HomeSignaling PathwaysImmunology/Inflammation-Cell Cycle/Checkpoint-ApoptosisPD-1/PD-L1

Anti-Mouse PD-1 Antibody (RMP1-14)

T78269

RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1 PD-L1 signaling.

In Stock

Size

QTY

Pembrolizumab

T99081374853-91-4

Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.

$218

In Stock

Size

QTY

Atezolizumab

T99021380723-44-3

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

$229

In Stock

Size

QTY

Nivolumab

T9907946414-94-4

Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.

$182

In Stock

Size

QTY

Avelumab

T99031537032-82-8

Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.

$289

In Stock

Size

QTY

BMS-202

T31461675203-84-5

BMS-202 (PD1-PDL1 inhibitor 2) is an inhibitor of the PD-1 (Programmed death- 1) PD-Ll (Programmed death-ligand 1) protein protein interaction.

In Stock

Size

QTY

Cited

Camrelizumab

T375351798286-48-2

Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1 PD-L1 with an IC50 of 0.70 nM. Camrelizumab exhibits anti-tumor activity and is well tolerated in cancers, including NSC-LC, ESCC, Hodgkin's lymphoma, and advanced HCC.

$163

Backorder

Size

QTY

Durvalumab

T111261428935-60-7

Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.

$228

In Stock

Size

QTY

AUNP-12 acetate

TP1076L

AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition to immune activation and antitumor activity.

$116

In Stock

Size

QTY

BMS-8

T268591675201-90-7

BMS-8 is a novel inhibitor of the PD-1 PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.

In Stock

Size

QTY

Tomivosertib

T34681849590-01-7

Tomivosertib (eFT508) is a potent and highly selective MNK1 and MNK2 inhibitor with an IC50 value of 1-2 nM.

In Stock

Size

QTY

Cited

Anti-Mouse PD-L1 Antibody (10F.9G2)

T78270

Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.

In Stock

Size

QTY

BMS-1001 hydrochloride

T105652113650-04-5

BMS-1001 hydrochloride is an orally active inhibitor of human PD-1 PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. BMS-1001 is capable of alleviating the PD-1 PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes.

In Stock

Size

QTY

BMS-1

T36551675201-83-8

BMS-1 (PD-1 PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene and the upregulation of PD-L1 allows Ys to evade the host immune system. High tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death.

In Stock

Size

QTY

Cited

INCB086550

T368992230911-59-6

INCB086550 (PD-1 PD-L1-IN-8) (example 24) is a PD-1 PD-L1 inhibitor, with an IC50 <= 10 nM.

$148

In Stock

Size

QTY

PD-1/PD-L1-IN-9

T96512628506-54-5In house

PD-1 PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1 PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.

In Stock

Size

QTY

PD-1/PD-L1-IN-10

T96162487550-41-2

PD-1 PD-L1-IN-10 is an orally available PD-1 PD-L1 inhibitor (IC50 value of 2.7 nM) that shows anti-tumor activity.

In Stock

Size

QTY

PROTAC PD-1/PD-L1 degrader-1

T401122447066-37-5

PROTAC PD-1 PD-L1 degrader-1, a Cereblon E3 ligand-based compound, is a PD-1 PD-L1 PROTAC that effectively inhibits the PD-1 PD-L1 interaction with an IC50 of 39.2 nM. It restores the suppressed immune response in a co-culture model of Hep3B OS-8 hPD-L1 cells and CD3 T cells and moderately decreases PD-L1 protein levels through a lysosome-dependent mechanism.

$253

In Stock

Size

QTY

BMS-1166

T56971818314-88-3

BMS-1166 is a potent inhibitor of the PD-1 PD-L1 interaction.

In Stock

Size

QTY

Fraxinellone

T6S007128808-62-0

1. Fraxinellone significantly reduced weight loss and diarrhea in mice and alleviated the macroscopic and microscopic signs of the disease. 2. Fraxinellone exhibited a variety of insecticidal activities including feeding-deterrent activity, inhibition of growth, and larvicidal activity. 3. Fraxinellone has effect in the midgut metabolism of Mythimna separata (M. separata), via protease (especially the weak alkaline trypsin-like enzyme), carboxylesterase and glutathione S-transferase.

In Stock

Size

QTY

Tislelizumab

T767031858168-59-8

Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.

In Stock

Size

QTY

Sintilimab

T353942072873-06-2

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.

$163

In Stock

Size

QTY

Nofazinlimab

T771022377845-98-0

Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody used to study unresectable hepatocellular carcinoma (uHCC) and metastatic colorectal cancer.

$263

In Stock

Size

QTY

N-deacetylated BMS-202

T121432310135-18-1

N-deacetylated BMS-202 is an inhibitor of PD-1 PD-L1 interactions and has potential anticancer activity for cancer research.

In Stock

Size

QTY

ARB-272572

T399142368182-63-0In house

ARB-272572 is a potent inhibitor of programmed cell death ligand 1 (PD-L1) signaling that induces PD-L1 homodimer interactions and produces immunostimulatory activity in human primary cells.

$159

In Stock

Size

QTY

LSD1-IN-27

T776352904571-94-2

LSD1-IN-27 is a potent LSD1 inhibitor with an IC50 value of 13 nM.LSD1-IN-27 inhibited the stemness and migration of gastric cancer cells.LSD1-IN-27 inhibited the expression of PD-L1 in BGC-823 and MFC cells.LSD1-IN-27 potentiated the T-cell immune response against gastric cancer.

$158

In Stock

Size

QTY

PD-1-IN-22

T123792349372-98-9In house

PD-1-IN-22 is a potent inhibitor of the programmed cell death-1 (PD-1) programmed cell death-ligand 1 (PD-L1) interaction, with an IC50 of 92.3 nM.

$117

In Stock

Size

QTY

PD-L1-IN-3

T793142953044-29-4

PD-L1-IN-3 (Compound 4a) functions as an inhibitor of the PD-1 PD-L1 axis, with an IC50 value of 4.97 nM for PD-L1 inhibition and an EC50 value of 2.70 μM for Jurkat T cell modulation. It antagonizes the PD-1 PD-L1 interaction by binding to the PD-L1 dimer, obstructing PD-1 signaling. This compound is utilized in research pertaining to lung cancer and melanoma [1].

In Stock

Size

QTY

CAY10678

T383691268709-57-4

CAY10678 is an mPGES-1 inhibitor that inhibits PD-1.CAY10678 reduces collagen deposition and T-cell depletion, and may be used to study melanoma.CASHIPS

In Stock

Size

QTY

Evixapodlin

T364872374856-75-2

Evixapodlin (PD-1 PD-L1-IN 7) is a human PD-1 PD-L1 protein protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities.

$113

In Stock

Size

QTY

LSD1-IN-24

T678714734-59-2

LSD1-IN-24 is a selective and potent LSD1 inhibitor with an IC50 value of 0.247 μM.LSD1-IN-24 induces PD-L1 expression and enhances the T cell killing response, and can be used in cancer-related diseases.

In Stock

Size

QTY

PDL-1 cpd 10

T93592767424-13-3

PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.

In Stock

Size

QTY

Sulfamethoxypyridazine

T084480-35-3

Sulfamethoxypyridazine (CL 13494) is a sulfanilamide antibacterial agent.

In Stock

Size

QTY

BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride

T40111L2691796-83-3In house

BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride, a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1) programmed cell death ligand 1 (PD-L1) inhibitor, inhibits the PD-1 PD-L1 interaction with an IC50 of 39.2 nM. It contains the target protein PD-1 PD-L1 ligand and PROTAC linker, which can be used to synthesize PROTAC PD-1 PD-L1 degrader-1 and has anticancer activity. Additionally, it serves as a diluent for the preparation of tablets for direct compression.

$189

In Stock

Size

QTY

BMS202 hydrochloride (1675203-84-5(free base))

T46962089334-95-0

BMS202 hydrochloride (1675203-84-5(free base)) (PD-1 PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1 PD-L1 interaction inhibitor (IC50: 18 nM). Biophysical studies demonstrate that BMS202 binds directly to PD-L1. Binding of BMS202 promotes PD-L1 dimerisation and blocks the PD-L1 PD1 interaction.

In Stock

Size

QTY

IMMH 010 maleate

T839702541982-47-0In house

IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.

$195

In Stock

Size

QTY

BMS-1001

T84702113650-03-4

BMS-1001 is a potent inhibitor of PD-1 PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).

In Stock

Size

QTY

Cetrelimab

T769452050478-92-5

Cetrelimab (JNJ 63723283) is a humanized anti-PD-1 monoclonal antibody that dose-dependently increases T cell-mediated cytokine production and stimulates cytokine expression. It is used in multiple myeloma and bladder cancer research.

$197

In Stock

Size

QTY

Adebrelimab

T768992247114-85-6

Adebrelimab (SHR-1316) is a humanized monoclonal antibody targeting PD-L1 with antitumor activity for the study of solid tumors.

$247

In Stock

Size

QTY

Ezabenlimab

T770032249882-54-8

Ezabenlimab (BI-754091) is a humanized monoclonal antibody targeting programmed cell death protein-1 with antitumor activity that blocks the interaction of PD-1 with PD-L1 and PD-L2, inhibits tumor growth in vivo, and can be used to study advanced solid tumors.

$197

In Stock

Size

QTY

Spartalizumab

T770751935694-88-4

Spartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity. It blocks the interaction with PD-L1 and PD-L2, making it suitable for studying undifferentiated thyroid cancer (ATC).

$178

In Stock

Size

QTY

Pacmilimab

T771282145091-51-4

Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.

$169

In Stock

Size

QTY

Budigalimab

T769362098225-93-3

Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1) with potential antitumor activity for the study of the anti-PD-1 inhibitor budigalimab in non-small cell lung cancer.

$197

In Stock

Size

QTY

Latikafusp

T770522552814-07-8

Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.Latikafusp initiates and prolongs cytotoxicity and memory T-cell activity and induces the generation of immunogenicity-mediated responses.

$538

In Stock

Size

QTY

Prolgolimab

T771332093956-19-3

Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.

$163

In Stock

Size

QTY

Feladilimab

T774332252518-85-5

Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist. Feladilimab binds to ICOS-expressing T cells, induces IFNγ, and increases PD-1 L1 expression. Feladilimab has anti-tumor activity and can be used to study cancer.

$247

In Stock

Size

QTY

PD-1-IN-17

T123771673560-66-1In house

PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.

$110

35 days

Size

QTY

ARB-272572 hydrochloride

T839762377524-19-9In house

ARB-272572 hydrochloride is a small molecule PD-L1 inhibitor with an IC50 value of 400 pM for PD-1 PD-L1 HTRF.ARB-272572 hydrochloride inhibits PD-1 PD-L1 cell signaling by inducing homologous interactions with PD-L1 proteins.

$195

In Stock

Size

QTY

Go to page 1

Page of 2